Icos's war of attrition By Ilan Zipkin
Staff Writer

Icos Corp. is relying on a broad pipeline of products, and multiple clinical trials with each product, to overcome the high rate of attrition inherent in drug development. With last week's setbacks involving LeukArrest and Pafase, ICOS has had more failures than successes to date. However, the company's pharma-like strategy includes the refinement of product development programs through early stage trials in more indications than will be successful.